SCHEMBL20114671

SCHEMBL20114671

Cc1nc(C)nc(-c2ccc(C#N)c(-n3c4ccccc4c4ccc(-c5nc(-c6ccccc6)nc(-c6ccccc6)n5)cc43)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 5/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
HPGD P15428 1/20 0.38
ABCG2 Q9UNQ0 5/20 0.37
CYP1A2 P05177 4/20 0.35
CYP2C19 P33261 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C9 P11712 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
CYP2D6 P10635 2/20 0.35
TSHR P16473 2/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HIF1A Q16665 1/20 0.34
MAT2A P31153 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20150334 0.97 L3MBTL1 (0.44) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20114523 0.96 ALDH1A1 (0.38) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20150330 0.96 MAT2A (0.36) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20150333 0.94 L3MBTL1 (0.41) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20114668 0.92 ALDH1A1 (0.40) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL19942782 0.92 L3MBTL1 (0.40) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20156172 0.91 CYP1A2 (0.34) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL20150302 0.91 AR (0.40) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20150324 0.90 AR (0.36) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL20150373 0.90 ALDH1A1 (0.38) L3MBTL1ALDH1A1LMNASMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421746-B2 Organic molecules, especially for use in organic optoelectronic devices CYNORA GMBH (DE) 2019-09-24 US disclosed
EP-3315581-B1 ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2019-01-02 EP disclosed
US-20180134686-A1 ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2018-05-17 US disclosed
US-20180134686-A1 ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2018-05-17 US disclosed
EP-3315581-A1 ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES CYNORA GMBH (DE) 2018-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134686-A1 ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES OR10J3, EPCAM, F12 L3MBTL1 2736/4885ALDH1A1 387/4885LMNA 3586/4885
US-10421746-B2 Organic molecules, especially for use in organic optoelectronic devices OR10J3, EPCAM, F12 L3MBTL1 2736/4885ALDH1A1 387/4885LMNA 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.